EZH2 and non-small cell lung carcinoma: From our in-house RNAseq data, we found that 60 out of 66 patients’ non-small cell lung cancer tissues had overexpressed EZH2 mRNA relative to the matched noncancerous lung tissues (average non-small cell lung cancer/noncancerous ratio of 6.27 ± 1.23).